Gordon James Freeman

Research topics

• Immune Cell Function and Interaction · 3 papers
• Cancer Immunotherapy and Biomarkers · 3 papers
• Immunotherapy and Immune Responses · 1 paper
• T-cell and B-cell Immunology · 1 paper
• Lymphoma Diagnosis and Treatment · 1 paper

Frequent co-authors

• Mary E Keir · 1 paper
• Manish J. Butte · 1 paper
• Arlene H. Sharpe · 1 paper
• Andrew J. Long · 1 paper
• Yoshiko Iwai · 1 paper
• Karen Bourque · 1 paper
• Tatyana Chernova · 1 paper
• Hiroyuki Nishimura · 1 paper

Papers

1. PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology · 2008 · 5,443 citations

   Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathology. Immune responses to foreign and self-antigens require specific and balanced responses to clear pathogens and tumors…

2. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine · 2000 · 5,360 citations

   PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells. Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features. We report here that the ligand of PD-1 (PD-L1) is…

3. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine · 2014 · 3,599 citations

   BACKGROUND: Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction…